📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
439 analysed today
FollowTelegram
439
Today
150,390
All-time analysed
43,074
Positive
6,687
Negative
91,884
Neutral
8,677
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
22 announcements match the current filters (relevance ≥ 5).
Medplus Subsidiary Receives Favorable Order from Telangana High Court
Optival Health Solutions Private Limited, a subsidiary of Medplus, has received a favorable order from the Hon’ble High Court of Telangana regarding a writ petition. The petition was related to an Assessment Order for AY:2020-21, concerning a disputed tax amount of ₹43.45 Crores. The High Court allowed the writ petition, resulting in no financial impact on Medplus. This development resolves a prior legal challenge and removes uncertainty related to the disputed tax assessment.
Key Highlights
Favorable order received from the High Court of Telangana on 21.11.2025
Disputed tax amount of ₹43.45 Crores for AY:2020-21
Order received on 23.11.2025
Writ petition allowed by the Telangana High Court
👀 What to Watch
Investors can view this as a positive development as it resolves a tax dispute. Monitor Medplus's website for further details.
Medplus subsidiary receives Drug License suspension order
Medplus Health Services Limited announced that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a Drug License for one of its stores in Maharashtra. The suspension is for fifteen days and was ordered by the Food and Drug Administration, Mumbai. This suspension is under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The company estimates a potential revenue loss of approximately ₹6.00 lacs due to this suspension.
Key Highlights
Drug License suspended for 15 days
Suspension order received on 03.12.2025
Potential Revenue Loss of Rs~6.00 lacs
Store situated at Charai- Thane, Maharashtra
👀 What to Watch
Investors should monitor the impact of the suspension on Medplus's overall revenue and profitability. Keep an eye on any further regulatory actions or updates from the company regarding this matter.
